Divi's Laboratories Signs Long-Term Agreement With Global Pharma Company

Divi's Laboratories Ltd. has entered into a long-term agreement with a global pharmaceutical company for the manufacturing and supply of advanced intermediates, the company said in an exchange filing on Friday.

To support this collaboration, Divi's Laboratories intends to invest between ₹6.50 billion and ₹7.00 billion from internal accruals to expand its manufacturing capacity. Advanced intermediates, which are compounds used in the synthesis of active pharmaceutical ingredients and are structurally closer to the final product than general intermediates, will be a key focus. 

The company anticipates that this agreement will make a significant contribution to its revenue and enhance its position in the custom synthesis space. However, the identity of the global pharmaceutical partner remains undisclosed due to a confidentiality agreement.